www.fdanews.com/articles/71585-maxim-receives-1-million-development-milestone-payment
Maxim Receives $1 Million Development Milestone Payment
April 27, 2005
Maxim Pharmaceuticals, Inc.
reported that it achieved a $1 million development milestone under an agreement
with Myriad Genetics. The milestone is based on the dosing of the first patient
in a Phase I clinical program designed to evaluate the safety and pharmacokinetic
profile of MPC-6827 in patients with advanced solid tumors.
Big
News Network